M&A Deal Summary

Argos Wityu Acquires Cisbio Bioassays SAS

On November 18, 2013, private equity firm Argos Wityu acquired life science company Cisbio Bioassays SAS from IBA for 25M EUR

Acquisition Highlights
  • This is Argos Wityu’s 1st transaction in the Life Science sector.
  • This is Argos Wityu’s 3rd largest (disclosed) transaction.
  • This is Argos Wityu’s 24th transaction in France.
Investment Fate
  • Cisbio Bioassays SAS was sold to a consortium of financial buyers in 2016.
  • Cisbio Bioassays SAS was sold to a publicly-traded strategic buyer in 2019.

M&A Deal Summary
Date 2013-11-18
Target Cisbio Bioassays SAS
Sector Life Science
Buyer(s) Argos Wityu
Sellers(s) IBA
Deal Type Divestiture
Deal Value 25M EUR

Target

Cisbio Bioassays SAS

Codolet, France
Cisbio Bioassays SAS is a life sciences company committed to improving human healthcare. Cisbio develops and markets products and technologies used for in vitro diagnostics and drug discovery.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Argos Wityu

Paris, France

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1989
PE ASSETS 1.8B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

Argos Soditic is a private equity firm that seeks majority or minority investments in small to medium sized companies headquartered throughout Europe. Argos Soditic will consider investments in public or private companies generating revenue of €20 to €600 million. The Firm's target investment size is €10 to €100 million. Funds are typically used to support management buyouts/buy-ins, divestitures, and growth capital needs. Argos Soditic is a generalist investor with interest in aerospace, manufacturing, distribution, business services, chemicals, marketing, industrial products, packaging, staffing, medical products, and healthcare services. Argos Soditic was formed in 1989 and is headquartered in Paris.

DEAL STATS #
Overall 45 of 80
Sector (Life Science) 1 of 1
Type (Divestiture) 12 of 15
Country (France) 24 of 41
Year (2013) 9 of 9
Size (of disclosed) 3 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-11-12 Aytos Soluciones Informáticas S.L.U.

Ecija, Spain

Aytos Soluciones Informáticas S.L.U. develops and implements of Administration Resource Planning (ARP) software solutions and Electronic Administration for Spanish public entities.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-01-01 Implanta

Milan, Italy

Implanta (Odos Service) offer a complete range of dental services. These services go from hygiene to implantology, with hospital class standards and the capability to handle, in addition to ordinary patients, those more fragile under long-term treatment at the hospital. Implanta (Odos Service) is based in Milan, Italy.

Buy -

Seller(S) 1

SELLER

IBA

Louvain-La-Neuve, Belgium
Category Company
Founded 1986
Sector Medical Products
Employees1,943
Revenue 429M EUR (2023)
DESCRIPTION

IBA we dare to develop innovative solutions pushing back the limits of science. We share ideas and know-how with our customers, our partners and leading experts to bring new solutions for the diagnosis and treatment of cancer and for the benefits of patients. We care of the well-being of patients and stakeholders as it is together that we complete our mission to Protect Enhance and Saves lives. IBA was founded in 1986 and is based in Louvain-La-Neuve, Belgium.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 2
Country (France) 1 of 1
Year (2013) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-04-01 IBA Molecular Imaging

Dulles, Vermont, United States

IBA Molecular is a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.

Buy €180M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-14 IBA Molecular Imaging

Dulles, Vermont, United States

IBA Molecular is a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.

Sell -
Mergr

Product

Company

Legal